Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Thursday that it has been granted Marketing Authorization for Ivermectin Newbury 10 mg/g cream in Denmark, marking the first approval in its Scandinavian registration process.
Approvals in Norway and Sweden are expected following completion of national reviews.
The cream treats facial redness caused by rosacea and is a generic version of Soolantra. The Scandinavian market for ivermectin cream is currently valued at approximately EUR2.8m, according to DLMI Nordic Pharma Insights.
CEO Lars Minor said that this marks Newbury's first product in dermatology and demonstrates its ability to expand its product portfolio. The company plans to launch Ivermectin Newbury in relevant markets once regulatory exclusivities and patents permit.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream